October 4, 2024

$1.075B

$825M

–

–

$250M

Undisclosed

–

Sanofi granted Recordati worldwide rights to commercialize Sanofi’s Enjaymo (sutimlimab), a humanized monoclonal antibody that targets and inhibits C1s in the classical complement pathway for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.

Sales / Co-Promotion Only

License Hand-off

• Sanofi granted Recordati worldwide rights to commercialize Enjaymo (sutimlimab).
• Enjaymo is a humanized monoclonal antibody targeting and inhibiting C1s in the classical complement pathway.
• It is used to treat cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.
• Sanofi will receive:
  • $825 million upfront.
  • Up to $250 million in commercial milestones if net sales meet or exceed top-end peak year sales expectations.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.